Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antisense

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    92 result(s) found for: Antisense. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2012-000833-38 Sponsor Protocol Number: ISIS329993-CS6 Start Date*: 2012-06-19
    Sponsor Name:Isis Pharmaceuticals, Inc.
    Full Title: A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients with Paroxysmal Atrial Fibrillation
    Medical condition: Atrial fibrillation (AF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004736-79 Sponsor Protocol Number: 1102-CT02 Start Date*: 2007-03-06
    Sponsor Name:Antisense Therapeutics Ltd.
    Full Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous inje...
    Medical condition: To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001044-22 Sponsor Protocol Number: ISIS721744-CS2 Start Date*: 2020-03-27
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double Blind, Placebo Controlled, Phase 2a Study to Assess the Clinical Efficacy of ISIS 721744, a Second Generation Ligand Conjugated Antisense Inhibitor of Prekallikrein, in Patient...
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-005878-10 Sponsor Protocol Number: ISIS757456-CS5 Start Date*: 2021-05-06
    Sponsor Name:Ionis Pharmaceuticals
    Full Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRX, an Antisense Inhibitor of Angiotensinogen Production, Ad...
    Medical condition: Chronic Heart Failure with Reduced Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000327-27 Sponsor Protocol Number: ISIS396443-CS2 Start Date*: 2017-01-26
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-004741-17 Sponsor Protocol Number: SPC2996-101 Start Date*: 2005-05-09
    Sponsor Name:Santaris Pharma
    Full Title: SPC2996 in Chronic Lymphocytic Leukaemia An open-labelled, international multicenter dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against Bcl-2, in patients with relapsed...
    Medical condition: Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in adults in the US and most of Western Europe. The incidence is 8100 to 12500 new cases in the US per year. CLL is a relatively ind...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001924-40 Sponsor Protocol Number: GED-0301-CD-003 Start Date*: 2017-02-21
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of adult and adolescent subjects with act...
    Medical condition: Active Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016693 10021315 Ileitis terminal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) BE (Completed) DE (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) FI (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) HR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002165-21 Sponsor Protocol Number: ISIS416858-CS5 Start Date*: 2017-11-23
    Sponsor Name:Ionis Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ISIS 416858 (IONIS-FXIRX an Antisense Inhibitor of Factor XI...
    Medical condition: Prevention of thrombosis while on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    20.0 10042613 - Surgical and medical procedures 10043634 Thrombosis prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) AT (Completed) NL (Completed) BG (Completed) BE (Completed) GR (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-005961-36 Sponsor Protocol Number: AEG35156-201 Start Date*: 2008-03-27
    Sponsor Name:Aegera Therapeutics Inc.
    Full Title: A Phase 1-2, Multicenter, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
    Medical condition: Advanced pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000621-12 Sponsor Protocol Number: ISIS396443-CS3A Start Date*: 2017-02-15
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002172-40 Sponsor Protocol Number: ISIS426115-CS2 Start Date*: 2014-01-08
    Sponsor Name:Isis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist) Administered Subcutane...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-002796-35 Sponsor Protocol Number: C4491011 Start Date*: 2021-01-07
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF 07285557) in Statin-Treated Participan...
    Medical condition: dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-005015-29 Sponsor Protocol Number: GS101-P2-CG Start Date*: 2005-08-03
    Sponsor Name:Les Laboratoires CTRS
    Full Title: A multicenter double-blind randomized study to investigate the efficacy and tolerability of three doses of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal ne...
    Medical condition: Patients suffering from keratitis or keratouveitits of infectious origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001836-72 Sponsor Protocol Number: ISIS416858-CS3 Start Date*: 2013-01-11
    Sponsor Name:Isis Pharmaceuticals, Inc.
    Full Title: An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Pati...
    Medical condition: Prophylaxis of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005388-33 Sponsor Protocol Number: GS101-P3-CG Start Date*: 2009-02-03
    Sponsor Name:Les Laboratoires CTRS
    Full Title: A MULTICENTRE DOUBLE-BLIND RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF GS-101 EYE DROPS, AN ANTISENSE OLIGONUCLEOTIDE, VERSUS PLACEBO ON INHIBITION OF CORNEAL NEOVASCULARIZATIO...
    Medical condition: Patients with corneal neovascularization, a major risk factor of corneal graft rejection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2021-001213-36 Sponsor Protocol Number: ISTH-02-211 Start Date*: 2021-06-20
    Sponsor Name:Isarna Therapeutics GmbH
    Full Title: TGF-BETa 2 antisense ISTH0036 for the Treatment of diabetic macular Edema (DME) and neovascular age-related maculaR degeneration (nAMD) The “BETTER” Study
    Medical condition: Neovascular age-related macular degeneration (nAMD) Diabetic Macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002421-35 Sponsor Protocol Number: ISIS304801-CS6 Start Date*: 2014-10-27
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10017339 Fredrickson Type I lipidaemia LLT
    18.1 100000004850 10060593 Fredrickson Type I lipidemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000493-35 Sponsor Protocol Number: ISIS-304801-CS17 Start Date*: 2016-02-17
    Sponsor Name:Akcea Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Partial Lipodystrophy
    Medical condition: Partial lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10053857 Partial lipodystrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) ES (Completed) NL (Completed) GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003434-93 Sponsor Protocol Number: ISIS-304801-CS16 Start Date*: 2015-01-07
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Ongoing) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000976-40 Sponsor Protocol Number: ION373-CS1 Start Date*: Information not available in EudraCT
    Sponsor Name:Ionis Pharmaceuticals, Inc
    Full Title: A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexand...
    Medical condition: Alexander Disease
    Disease: Version SOC Term Classification Code Term Level
    22.1 10010331 - Congenital, familial and genetic disorders 10083059 Alexander disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:50:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA